{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:25:56Z","timestamp":1791498356206,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4209-9","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T13:45:52Z","timestamp":1521121552000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Anik\u00f3","family":"Mar\u00e1z","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienn","family":"Cserh\u00e1ti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Uhercs\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Szil\u00e1gyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"R\u00e9v\u00e9sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e1ta","family":"K\u00f3sz\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Kah\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"issue":"22","key":"4209_CR1","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584\u201390.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4209_CR2","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1021\/jm0204183","volume":"46","author":"L Sun","year":"2003","unstructured":"Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2003;46(7):1116\u20139.","journal-title":"J Med Chem"},{"issue":"1","key":"4209_CR3","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327\u201337.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4209_CR4","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","volume":"101","author":"AM O'Farrell","year":"2003","unstructured":"O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597\u2013605.","journal-title":"Blood"},{"issue":"5","key":"4209_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4161\/cbt.2.5.446","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"4209_CR6","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1158\/1535-7163.MCT-03-0156","volume":"5","author":"O Potapova","year":"2006","unstructured":"Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther. 2006;5(5):1280\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"4209_CR7","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQ Chow","year":"2007","unstructured":"Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25(7):884\u201396.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4209_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324.","journal-title":"N Engl J Med"},{"issue":"4","key":"4209_CR9","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/sj.bjc.6605552","volume":"102","author":"D Cella","year":"2010","unstructured":"Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010;102(4):658\u201364.","journal-title":"Br J Cancer"},{"key":"4209_CR10","unstructured":"NCCN Guideline: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf . Accessed 6 Feb 2018."},{"issue":"5","key":"4209_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/annonc\/mdw328","volume":"27","author":"B Escudier","year":"2016","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal Cell Carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(5):58\u201368.","journal-title":"Ann Oncol"},{"issue":"5","key":"4209_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU Guidelines on Renal Cell Carcinoma: 2014 Update. Eur Urol. 2015;67(5):913\u201324.","journal-title":"Eur Urol"},{"issue":"5","key":"4209_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1756287212454933","volume":"4","author":"M Schmidinger","year":"2012","unstructured":"Schmidinger M, Larkin J, Ravaud A. Experience with sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2012;4(5):253\u201365.","journal-title":"Ther Adv Urol"},{"issue":"12","key":"4209_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","volume":"30","author":"RJ Motzer","year":"2012","unstructured":"Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30(12):1371\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4209_CR15","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/cncr.26440","volume":"118","author":"CH Barrios","year":"2012","unstructured":"Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer. 2012;118(5):1252\u20139.","journal-title":"Cancer"},{"issue":"2","key":"4209_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/annonc\/mdv589","volume":"27","author":"S Bracarda","year":"2016","unstructured":"Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, et al. Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2016;27(2):366.","journal-title":"Ann Oncol"},{"key":"4209_CR17","unstructured":"Escudier B. ESMO 2017: Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC. http:\/\/www.esmo.org\/Conferences\/ESMO-2017-Congress\/News-Articles\/Nivolumab-Plus-Ipilimumab-versus-Sunitinib-in-First-Line-Treatment-for-Advanced-or-Metastatic-RCC . Accessed 10 Sept 2017."},{"key":"4209_CR18","unstructured":"Sutent SMPC: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/000687\/WC500057689.pdf . Accessed 3 Oct 2014."},{"issue":"1\u20132","key":"4209_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1013129128673","volume":"20","author":"RS Kerbel","year":"2001","unstructured":"Kerbel RS. Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Rev. 2001;20(1\u20132):1\u20132.","journal-title":"Cancer Metastasis Rev"},{"issue":"1\u20132","key":"4209_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1023\/A:1013172910858","volume":"20","author":"RS Kerbel","year":"2001","unstructured":"Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001;20(1\u20132):79\u201386.","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"4209_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8(8):579\u201391.","journal-title":"Nat Rev Cancer"},{"issue":"32","key":"4209_CR22","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1200\/JCO.2012.41.9242","volume":"30","author":"JN Bottsford-Miller","year":"2012","unstructured":"Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012;30(32):4026\u201334.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4209_CR23","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1515\/BC.2009.144","volume":"390","author":"PA Gerber","year":"2009","unstructured":"Gerber PA, Hippe A, Buhren BA, Muller A, Homey B. Chemokines in tumor associated angiogenesis. Biol Chem. 2009;390(12):1213\u201323.","journal-title":"Biol Chem"},{"issue":"23","key":"4209_CR24","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","volume":"17","author":"KJ Gotink","year":"2011","unstructured":"Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res. 2011;17(23):7337\u201346.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4209_CR25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1535-7163.MCT-09-1106","volume":"9","author":"HJ Hammers","year":"2010","unstructured":"Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek R, Jaspers J, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010;9(6):1525\u201335.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"4209_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1158\/1535-7163.MCT-14-0208","volume":"14","author":"R Adelaiye","year":"2015","unstructured":"Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, et al. Sunitinib dose-escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther. 2015;14(2):513\u201322.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"4209_CR27","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.urolonc.2013.10.004","volume":"32","author":"GA Bjarnason","year":"2014","unstructured":"Bjarnason GA, Khalil B, Hudson JM, Williams R, Milot LM, Atri M, et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. Urol Oncol. 2014;32(4):480\u20137.","journal-title":"Urol Oncol"},{"issue":"2","key":"4209_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66(2):357\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4209_CR29","doi-asserted-by":"crossref","unstructured":"NCI CTCAE https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf . Accessed 14 June 2010.","DOI":"10.2118\/0310-014-TWA"},{"issue":"3","key":"4209_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","volume":"2","author":"CC Schag","year":"1984","unstructured":"Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187\u201393.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4209_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"4209_CR32","doi-asserted-by":"crossref","unstructured":"Bex A, Mulders P, Jewett M, et al. Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). Abstract presented at: ESMO 2017 Congress; September 8\u201312, 2017; Madrid, Spain. Abstract LBA35.","DOI":"10.1093\/annonc\/mdx440.030"},{"issue":"9286","key":"4209_CR33","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","volume":"358","author":"GH Mickisch","year":"2001","unstructured":"Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966\u201370.","journal-title":"Lancet"},{"issue":"1","key":"4209_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","volume":"6","author":"E Jonasch","year":"2001","unstructured":"Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34\u201355.","journal-title":"Oncologist"},{"key":"4209_CR35","doi-asserted-by":"publisher","first-page":"717295","DOI":"10.1155\/2014\/717295","volume":"2014","author":"MZ Aslam","year":"2014","unstructured":"Aslam MZ, Matthews PN. Cytoreductive nephrectomy for metastatic renal cell carcinoma: a review of the historical literature and its role in the era of targeted molecular therapy. ISRN Urol. 2014;2014:717295. https:\/\/doi.org\/10.1155\/2014\/717295 .","journal-title":"ISRN Urol"},{"key":"4209_CR36","doi-asserted-by":"crossref","unstructured":"Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU Int. 2016;117(1):110\u20137.","DOI":"10.1111\/bju.12940"},{"issue":"5","key":"4209_CR37","doi-asserted-by":"publisher","first-page":"555","DOI":"10.5301\/tj.5000342","volume":"101","author":"J Kucharz","year":"2015","unstructured":"Kucharz J, Dumnicka P, Kuzniewski M, Kusnierz-Cabala B, Herman RM, Krzemieniecki K. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study. Tumori. 2015;101(5):555\u20139.","journal-title":"Tumori"},{"key":"4209_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3109\/07357901003631080","volume":"28","author":"M Schmidinger","year":"2010","unstructured":"Schmidinger M, Arnold D, Szczylik C, Wagstaff J, Ravaud A. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Cancer Investig. 2010;28:856\u201364.","journal-title":"Cancer Investig"},{"issue":"9","key":"4209_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","volume":"103","author":"BI Rini","year":"2011","unstructured":"Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011;103(9):763\u201373.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"4209_CR40","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/bjc.2015.368","volume":"113","author":"F Donskov","year":"2015","unstructured":"Donskov F, Michaelson MD, Puzanov I, Davis MP, Bjarnason GA, Motzer RJ, et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer. 2015;113(11):1571\u201380.","journal-title":"Br J Cancer"},{"issue":"12","key":"4209_CR41","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","volume":"14","author":"BI Rini","year":"2013","unstructured":"Rini BI, Melichar B, Ueda T, Gr\u00fcnwald V, Fishman MN, Arranz JA, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14(12):1233\u201342.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4209_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ctrv.2010.08.006","volume":"37","author":"HJ Klumpen","year":"2011","unstructured":"Klumpen HJ, Samer CF, Mathijssen RH, Schellens JH, Gurney H. Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev. 2011;37(4):251\u201360.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"4209_CR43","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1158\/1078-0432.CCR-08-1893","volume":"15","author":"BE Houk","year":"2009","unstructured":"Houk BE, Bello CL, Kang D, Amantea M. A population pharmaco- kinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15(7):2497\u2013506.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4209_CR44","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116(10):2610\u201321.","journal-title":"J Clin Invest"},{"issue":"1","key":"4209_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16\u201324.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4209_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, et al. Safety, pharmacokinetic, and antitumor activity of SU 11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25\u201335.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4209_CR47","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ajco.12296","volume":"11","author":"N Mitchell","year":"2015","unstructured":"Mitchell N, Fong PC, Broom RJ. Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma. Asia Pac J Clin Oncol. 2015;11(3):e1\u20135. https:\/\/doi.org\/10.1111\/ajco.12296 .","journal-title":"Asia Pac J Clin Oncol"},{"issue":"23","key":"4209_CR48","doi-asserted-by":"publisher","first-page":"5400","DOI":"10.1002\/cncr.25583","volume":"116","author":"IN Zama","year":"2010","unstructured":"Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, Heng DY, et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 2010;116(23):5400\u20136.","journal-title":"Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4209-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4209-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4209-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T01:28:26Z","timestamp":1719883706000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4209-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4209"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4209-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"12 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the procedures performed were in full accordance with the ethical standards of the appropriate national and institutional committees on human experimentation and with the Helsinki Declaration. The study was approved by the Regional Human Biomedical Research Ethics Committee, Albert Szent-Gy\u00f6rgyi Health Center, University of Szeged, Hungary (registration number: WHO 3482\/2014). The enrolled patients gave their written informed consent before being registered in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anik\u00f3 Mar\u00e1zhas received honoraria from Bayer, Bristol-Myers Squibb, and has served on advisory boards for Novartis. J\u00e1nos R\u00e9v\u00e9sz has served on advisory boards for Novartis and Pfizer.Adrienn Cserh\u00e1ti,Gabriella Uhercs\u00e1k,\u00c9va Szil\u00e1gyi,Zolt\u00e1n Varga,J\u00e1nos R\u00e9v\u00e9sz,Ren\u00e1ta K\u00f3sz\u00f3,Linda Varga,Zsuzsanna Kah\u00e1ndeclares that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"296"}}